Robert C. Wang, MD

Areas of Focus  |  Vitreoretinal Surgery, Uveitis, Medical Retina, Director of Clinical Research – Texas Retina Associates, Plano

Office Locations  | Dallas Main, Dallas North, Plano, Sherman

Certification  |  American Board of Ophthalmology

Languages Spoken  | English

“I continually strive to learn more. All of my endeavors — as a clinician, researcher, surgeon, friend and volunteer — are for the ultimate care of my patients.”


University of Southern California

Doheny Eye Institute
Los Angeles, California

Harvard University
Massachusetts Eye and Ear Infirmary
Boston, Massachusetts


Havener Eye Center

Columbus, Ohio


Riverside Methodist Hospital
Columbus, Ohio

Medical School

The Ohio State University
Columbus, Ohio

  • American Academy of Ophthalmology
  • American Uveitis Society
  • American Society of Retina Specialists
  • Texas Medical Association
  • Texas Ophthalmological Association
  • Dallas County Medical Society
  • Dallas Academy of Ophthalmology
  • Primary Investigator, Acelyrin – A Phase IIb Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in subjects with Non-Infectious, Intermediate-, Posterior-, or Pan-Uveitis
  • Primary Investigator, Odyssey – CLS1002-202 – A Phase IIB Study of Suprachoroidally Administered CLS-AX In Participants with Neovascular Age-Related Macular Degeneration
  • Primary Investigator, iGain – IGS01 – A Multi-center, Natural History, Non-investigational Study Evaluating Biomarkers In Participants With Geographic Atrophy(GA) Secondary to Age-related Macular Degeneration (AMD)
  • Primary Investigator, Leopard – Efficacy and Safety of Dexamethasone Ophthalmic Suspension Eye Drops in Uvetic and Post-surgical Macular Edema – The Leopard Study
  • Primary Investigator, Neptune – PVT-2201-201 – A Phase II Randomized, Double-masked, Dose-ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Active Non-Infectious Intermediate-, Posterior-, and Panuveitis


  • Primary Investigator, PAVIA – EYP-1901-204 – A Phase II, Multi-center, Prospective, Double-masked, Parallel Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), Compared to Sham for the Improvement of Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR)
  • Primary Investigator, AMEND – QA102-CS2021 – A Phase II, Double-masked, Randomized, Placebo-controlled, Dose-response Study Assessing the Safety and Efficacy of QA102 in Subjects with Dry Age-related Macular Degeneration (AMD)
  • Primary Investigator, ReGAIN – SPIAM-302 – A Phase II, Double-masked, Randomized, Placebo-controlled, Dose-response Study Assessing the Safety and Efficacy of QA102 in Subjects with Dry Age-Related Macular Degeneration (AMD)
  • Primary Investigator, OPTYK-1 – ESK-001-014 – A Proof-of-Concept, Randomized, Double-masked Study to Evaluate the Efficacy and Safety of ESK-001 in Patients with Active Noninfectious Intermediate, Posterior, or Panuveitis
  • Sub-Investigator, TYNI – TRA-TYNI-22-001 – The Use of Two YUTIQ versus Sham for Treatment of Chronic Non-infectious Intraocular Inflammation Affecting the Posterior Segment
  • Wang RC. Safety and Efficacy of Brepocitinib, a TYK2/JAK1 Inhibitor, in Active Non-Infectious Uveitis: A 52-Week Phase 2 Study (NEPTUNE). Abstract Submitted.
  • Bello NR, Wang RC, Henry CR, Singer M, Hopkins S, Billawala K, Boss J, Mammo DA. Intraocular Pressure Outcomes following Suprachoroidal Triamcinolone Acetonide in Patients with Glaucoma, Ocular Hypertension, or Steroid Response.
  • Yeh S, Khurana RN, Shah M, Henry CR, Wang RC, Kissner JM, Ciulla TA, Noronha G; PEACHTREE Study Investigators. Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis: Phase 3 Randomized Trial. Ophthalmology. 2020 Jul;127(7):948-955.
  • Henry C, Shah M, Barakat M, Dayani P, Wang RC, Khurana R, … Ciulla T. Suprachoroidal CLS-TA for Non-infectious Uveitis: An Open-label, Safety Trial (AZALEA). British Journal of Ophthalmology, 2022 Jun;106(6):802-806; Epub 2021 Feb 5.
  • Nguyen Q, Anesi S, Chexal S, Chu DS, Dayani PN, Leng T, Meleth AD, Sallam AA, Sheppard JD, Silverstein SM, Toyos M, Wang RC, Foster CS. Management of Repository Corticotropin Injection Therapy for Non-infectious Uveitis: A Delphi study. Acta Ophthalmologica, 2021 Sep;99(6):669-678; Epub 2021 Mar 9.
  • Khurana RN, Merrill P, Yeh S, Suhler E, Barakat MR, Uchiyama E, Henry CR, Shah M, Wang RC, Kapik B, Ciulla T. Extension Study of the Safety and Efficacy of CLS-TA for Treatment of Macular Edema Associated with Non-infectious Uveitis (MAGNOLIA). British Journal of Ophthalmology, 2022 Aug;106(8):1139-1144; Epub 2021 Mar 12.
  • Yeh S, Khurana R Shah M, Henry C, Wang RC, Kissner J, … PEACHTREE, S. I. Efficacy and Safety of Suprachoroidal CLS-TA for Macular Edema Secondary to Noninfectious Uveitis: Phase 3 Randomized Trial. Ophthalmology, 2020 Jul;127(7):948-955; Epub 2020 Jan 10.
  • Yeh S, Kurup S, Wang RC, Foster C, Noronha G, Nguyen Q, … DOGWOOD, S. T. Suprachoroidal Injection of Triamcinolone Acetonide, CLS-TA, for Macular Edema Due to Noninfectious Uveitis: A Randomized, Phase 2 Study (DOGWOOD). Retina, 2019 Oct;39(10):1880-1888.
  • Yu J, Agrón E, Clemons T, Domalpally A, van Asten F, Keenan T, … Age-Related Eye Disease Study 2 Research Group. Natural History of Drusenoid Pigment Epithelial Detachment Associated with Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report No. 17. Ophthalmology, 2019 Feb;126(2):261-273; Epub 2018 Aug 22.
  • Keenan T, Agrón E, Domalpally A, Clemons T, van Asten F, Wong W, … AREDS2 Research Group. Progression of Geographic Atrophy in Age-related Macular Degeneration: AREDS2 Report Number 16. Ophthalmology, 2018 Dec;125(12):1913-1928; Epub 2018 Jul 27.
  • Wang participates in various speaking engagements, especially on the topic of uveitis.
  • Adjunct Faculty, University of Texas-Southwestern
  • Reviewer, American Journal of Ophthalmology
  • Reviewer, OSLI Retina
  • Evans Scholar, Ohio State University — Dr. Wang received this coveted, full-tuition undergraduate scholarship and still contributes to the program today to allow other students the chance to attend college.
  • Active Supporter, Retina Foundation of the Southwest